Potential Treatment Option for Beckwith-Wiedmann Syndrome and Russell-Silver Syndrome

Recent research has discovered a new, potential treatment option that could provide an early intervention for Beckwith-Wiedmann syndrome and Russell-Silver syndrome. Published in Cell Reports, this study could provide the…

Continue Reading Potential Treatment Option for Beckwith-Wiedmann Syndrome and Russell-Silver Syndrome
Results Available from GS030 Study for RP in NHP
https://pixabay.com/photos/animals-lemurs-wildlife-zoo-monkey-1010643/

Results Available from GS030 Study for RP in NHP

Recently, biopharmaceutical company GenSight Biologics ("GenSight") announced the publication of data from a study evaluating GS030-Drug Products (GS030-DP or "GS030") as a potential treatment option for retinitis pigmentosa (RP). Although…

Continue Reading Results Available from GS030 Study for RP in NHP
The FDA Has Approved Niraparib (Zejula) for Platinum-Sensitive Recurrent Ovarian Cancer
source: pixabay.com

The FDA Has Approved Niraparib (Zejula) for Platinum-Sensitive Recurrent Ovarian Cancer

Dr. Oliver Dorigo of the Stanford University Medical Center was the medical source for an article featured in Oncology. Dr. Dorigo explained that if a woman with ovarian cancer has…

Continue Reading The FDA Has Approved Niraparib (Zejula) for Platinum-Sensitive Recurrent Ovarian Cancer
Each New Discovery Brings Scientists Closer to Finding the Cause of Alzheimer’s Disease
source: pixabay.com

Each New Discovery Brings Scientists Closer to Finding the Cause of Alzheimer’s Disease

Scientists are researching Alzheimer’s disease (AD) from all angles and gradually closing in on the cause of the disease. According to an article in Neuroscience News, a discovery by researchers…

Continue Reading Each New Discovery Brings Scientists Closer to Finding the Cause of Alzheimer’s Disease
First Patient Dosed in CA-4948 Trial for Hematologic Malignancies
source: pixabay.com

First Patient Dosed in CA-4948 Trial for Hematologic Malignancies

The first patient has been dosed in a Phase 1 clinical trial, which is exploring Curis Inc.'s CA-4948 in conjunction with ibrutinib for hematologic malignancies. Examples of hematologic malignancies include…

Continue Reading First Patient Dosed in CA-4948 Trial for Hematologic Malignancies